These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23335290)

  • 1. Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.
    Hoehn ME; Kelly SR; Wilson MW; Walton RC
    Pediatr Blood Cancer; 2013 Jul; 60(7):E35-7. PubMed ID: 23335290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
    Kurt RA; Yalçindag N; Atilla H; Arat M
    Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.
    Chiang TH; Walt JG; McMahon JP; Mansfield JE; Simonyi S
    Can J Clin Pharmacol; 2007; 14(2):e240-5. PubMed ID: 17622671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye: comment.
    Tam PM; Young AL; Lam PT
    Clin Exp Ophthalmol; 2010 Jan; 38(1):84-5. PubMed ID: 20447110
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE; Perry HD
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review: topical ophthalmic use of cyclosporin A.
    Utine CA; Stern M; Akpek EK
    Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
    Rao SN; Rao RD
    Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers].
    Egorova GB; Mitichkina TS; Fedorov AA; Shamsudinova AR
    Vestn Oftalmol; 2015; 131(1):36-42. PubMed ID: 25872385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical cyclosporine for treatment of ocular surface disease.
    Foulks GN
    Int Ophthalmol Clin; 2006; 46(4):105-22. PubMed ID: 17060797
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrating restasis into the management of dry eye.
    Pflugfelder SC
    Int Ophthalmol Clin; 2006; 46(4):101-3. PubMed ID: 17060796
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of topical cyclosporine for the treatment of dry eye disease.
    Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE
    Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
    Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
    Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.